|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 2018美国卒中协会/美国心脏协会急性缺血性卒中患者早期管理指南显示文摘2013年《急性缺血性卒中患者早期管理指南》发表后,高质量的新证据使急性缺血性卒中(acute ischemic stroke,AIS)患者的循证治疗发生重大变化。2013年以来,在美国心脏协会(American Heart Association,AHA)重点关注的与AIS患者管理相关专题的更新、指南及科学声明中,已经整合了这些证据。 | Powers WJ Rabinstein AA Ackerson T 车睿雯 高瑜 吉康祥 吉训明 蒋芳 李传辉 李芳芳 刘宇嘉 吕彦锋 马红蕊 任明 魏文静 王彬成 吴川杰 吴隆飞 喻琬童 张莉 | 2018 | 中国脑血管病杂志2018，15，3： | 953 |
| 2 | 2018美国卒中协会/美国心脏协会急性缺血性卒中患者早期管理指南显示文摘(接第3期)3一般性支持治疗和急诊处理3.1气道、呼吸和氧饱和3.1.1急性卒中并发意识障碍及延髓性麻痹影响气道功能者,建议进行气道支持及辅助通气。推荐等级Ⅰ,证据水平C-EO,同2013版AIS指南。3.1.2建议补充氧气以保持氧饱和度>94%。推荐等级Ⅰ,证据水平C-LD,同2013版AIS指南。3.1.3 AIS患者无低氧表现不建议补充氧气。 | Powers WJ Rabinstein AA Ackerson T 车睿雯 高瑜 吉康祥 吉训明 蒋芳 李传辉 李芳芳 刘宇嘉 吕彦锋 马红蕊 任明 魏文静 王彬成 吴川杰 吴隆飞 喻琬童 张莉 | 2018 | 中国脑血管病杂志2018，15，4： | 55 |
| 3 | Tumor necrosis factor-α and interleukin-6 in cirrhotic patients with spontaneous bacterial peritonitis显示文摘AIM:To evaluate the role of tumor necrosis factor-α(TNF-α) and interleukin-6(IL-6) in cirrhotic patients who have hepatic and renal impairment with spontaneous bacterial peritonitis(SBP).METHODS:We prospectively studied 120 cirrhotic patients with SBP and 80 cirrhotic patients with sterile ascitic fluid.They included 144 males and 56 females with ages ranging between 34 and 62 years.The diagnosis of cirrhosis was established by clinical and laboratory criteria that did not require histological confirmation.The severity of underlying liver disease was evaluated using Pugh's modification of Child's criteria(Child-Pugh scores).Ascitic fluid was sent to the laboratory for cell count,culture,sensitivity testing,and measurement of chemical elements(i.e.,albumin,glucose).Specimens were inoculated into aerobic and anaerobic blood culture bottles.Serum and ascitic fluid were also collected in sterile tubes at study entry(before the initiation of antibiotic treatment) and 48 h later.Assays for TNF-α and IL-6 in the serum and ascitic fluid were performed with an immunoenzymometric assay using manufacture's instructions.RESULTS:Cytokine levels in serum and ascitic fluid were significantly higher in the patients with SBP.(plasma TNF-α:135.35 ng/mL ± 11.21 ng/mL vs 92.86 ng/mL ± 17.56 ng/mL,P < 0.001;plasma IL-6:32.30 pg/mL ± 7.07 pg/mL vs 12.11 pg/mL ± 6.53 pg/mL,P < 0.001;ascitic fluid TNF-α:647.54 ± 107.11 ng/mL vs 238.43 ng/mL ± 65.42 ng/mL,P < 0.001);ascitic fluid IL-6:132.84 ng/mL ± 34.13 vs 40.41 ± 12.85 pg/mL,P < 0.001).About 48(40%) cirrhotic patients with SBP developed renal and hepatic impairment and showed significantly higher plasma and ascitic fluid cytokine levels at diagnosis of infection.[(plasma TNF-α:176.58 ± 17.84 vs 135.35 ± 11.21 ng/mL)(P < 0.001) and(IL-6:57.83 ± 7.85 vs 32.30 ± 7.07 pg/mL)(P < 0.001);ascitic fluid TNF-α:958.39 ± 135.72 vs 647.54 ± 107.11 ng/mL,(P < 0.001),ascitic fluid IL-6:654.74 ± 97.43 vs 132.84 ± 34.13 pg/mL,(P < 0.001)].Twenty nine patients(60.4%) with SBP and renal impairment died whereas,only four patients(5.55%) with SBP but without renal impairment died from gastrointestinal hemorrhage(P < 0.0005).CONCLUSION:It appears that TNF-α production may enhance liver cell injury and lead to renal impairment.This correlated well with the poor prognosis and significantly increased mortality associated with SBP in cirrhotic patients. | Muhammed AM Suliman Fawzy MH Khalil Salam SA Alkindi Anil V Pathare Ali AA Almadhani Neveen AAI Soliman | 2012 | World Journal of Gastrointestinal Pathophysiology2012，3，5： | 39 |
| 4 | 伴有cic基因重排的肉瘤是一种具有侵袭性预后的独特病种:115例临床病理和分子研究(英)显示文摘t(4;19)或t(10;19)染色体易位可导致CIC-DUX4基因融合,这是在EWSR1基因表达沉默的小圆细胞肿瘤中最易发现的遗传学异常。这类肿瘤是否应视为变异型尤文肉瘤(非典型尤文肉瘤)或作为独立的病理学类型具有争议。WHO分类中在获得明确的临床证据之前,临时性将伴有cic重排的肿瘤归类为未分化小圆细胞肉瘤。 | Antonescu CR Owosho AA Zhang L 曹琪(译) 张建中(校) | 2017 | 诊断病理学杂志2017，24，12： | 34 |
| 5 | 手术夹闭与血管内弹簧栓塞对动脉瘤蛛网膜下腔出血后症状性血管痉挛的发生率与预后的影响显示文摘 | Rabinstein AA Pichelmann MA Friedman JA 李林 | 2003 | 中国微侵袭神经外科杂志2003，8，4： | 29 |
| 6 | IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treat- ment of Cancer Brain Tumor Group显示文摘 | van den Bent M J Dubbink HJ Marie Y Brandes AA Taphoorn MJ Wesseling P Frenay M Tijssen CC Lacombe D ldbaih A van Marion R Kros JM Dinjens WN Gorlia T. Sanson M. | 2010 | 中国神经肿瘤杂志2010，8，1： | 22 |
| 7 | 动脉瘤性蛛网膜下腔出血的治疗指南(ASA/AHA 2012版)(下)显示文摘4aSAH的临床表现及诊断aSAH的临床表现是疾病中最具有特征性的表现之一。清醒aSAH患者的标志性主诉是“有生以来最严重的头痛”,约80%能够提供病史的患者会这样描述。这种头痛的特点是极其突然出现且迅速达到最剧烈的程度(电击样头痛)。 | Connolly ES Rabinstein AA Carhuapoma 孙澎 范存刚 张庆俊 | 2013 | 中国脑血管病杂志2013，10，4： | 23 |
| 8 | 土壤中棉花黄萎病菌SYBR Green Ⅰ荧光RT-PCR定量检测技术研究显示文摘为实现田间土壤棉花黄萎病菌的早期检测,建立了土壤中棉花黄萎病菌的SYBR Green I荧光定量PCR检测方法。以含342bp PCR扩增产物的阳性质粒为参考,构建了标准曲线,并对该曲线的特异性、敏感性、可重复性进行了评价。结果表明,该方法具有快速、特异性强、敏感度高等特点。检测范围在3.8×103-3.8×108copies/μL之间有良好的线性关系,相关系数R2为0.996,扩增效率为101.5%,灵敏度比常规PCR方法高102倍。 | 肖蕊 余真真 Elsharawy AA 魏锋 杨家荣 | 2011 | 菌物学报2011，30，4： | 19 |
| 9 | 动脉瘤性蛛网膜下腔出血的治疗指南(ASA/AHA2012版)(上)显示文摘鉴于对循证医学结论的日益重视,美国心脏协会(American Heart Association,AHA)制定了各类医学热点的指南,并致力于使这些指南与时俱进。此前由AHA卒中委员会资助完成的动脉瘤性蛛网膜下腔出血(aSAH)指南已于1994年和2009年发布[1-2]。其中,2009版指南涵盖了截止于2006年11月1日的文献[2]。2012版指南主要包括2006年11月1日—2010年5月1日发表的文献。写作组力求借助新资料扩充先前版本推荐的内容。需要特别指出的是,本指南中涵盖的新资料使先前的推荐发生了一些改变。 | Connolly ES Jr Rabinstein AA Carhuapoma JR 孙澎 范存刚 张庆俊 | 2013 | 中国脑血管病杂志2013，10，3： | 17 |
| 10 | 经冠状动脉造影证实的初次冠状动脉支架内血栓形成长期临床预后:431例临床分析显示文摘本研究(Dutch Stent Thrombosis Registry)为一项多中心研究,纳入了2004年1月至2007年2月期间经造影确认的ST病例。本研究ST的定义根据ARC分类为明确的血栓形成。根据事件发生的时间分为急性(24h之内)、亚急性(24h~30d)、晚期(30d~1年)和极晚期(1年以后)血栓形成。 | van Werkum JW Heestermans AA de Korte FI 张闻多 | 2009 | 中国心血管杂志2009，14，4： | 15 |
| 11 | Differential regulations of blood pressure and perturbed metabolism by total ginsenosides and conventional antihypertensive agents in spontaneously hypertensive rats显示文摘 | Ji-ye AA Guang-ji WANG Hai-ping HAO Qing HUANG Yi-hong LU Bei YAN Wei-bin ZHA Lin-sheng LIU An KANG | 2010 | Acta Pharmacologica Sinica2010，31，8： | 14 |
| 12 | Immunoexpression of cyclooxygenase-2 in primary gastric carcinomas and lymph node metastases显示文摘AIM: To evaluate immunoexpression of cyclooxygenase-2 (COX-2) in primary gastric carcinomas and respective lymph node metastases. METHODS: Immunohistochemistry to analyze COX-2 expression was performed on tissue microarray slices obtained from 36 specimens of gastrectomy and satellite lymph nodes from patients with gastric carcinoma. RESULTS: Immunostaining was seen in most cases, and COX-2 expression was higher in lymph node me-tastases than in corresponding primary gastric tumors of intestinal, diffuse and mixed carcinomas, with a statistically signif icant difference in the diffuse histotype (P = 0.0108). CONCLUSION: COX-2 immunoexpression occurs frequently in primary gastric carcinomas, but higher expression of this enzyme is observed in lymph node metastases of the diffuse histotype. | Paulo RC Almeida Francisco VA Ferreira Cássio C Santos Francisco D Rocha-Filho Raul RP Feitosa Esther AA Falco Belise K Cavada Roberto CP Lima-Júnior Ronaldo A Ribeiro | 2012 | World Journal of Gastroenterology2012，18，8： | 14 |
| 13 | The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation显示文摘Epalrestat is an inhibitor of aldose reductase in the polyol pathway and is used for the management of diabetic neuropathy clinically.Our pilot experiments and accumulated evidences showed that epalrestat inhibited polyol pathway and reduced sorbitol production,and suggested the potential renal protection effects of epalrestat on diabetic nephropathy (DN).To evaluate the protective effect of epalrestat,the db/db mice were used and exposed to epalrestat for 8 weeks,both the physiopathological condition and function of kidney were examined.For the first time,we showed that epalrestatmarkedlyreduced albuminuria and alleviated the podocyte foot process fusion and interstitial fibrosis of db/db mice.Metabolomics was employed,and metabolites in the plasma,renal cortex,and urine were profiled using a gas chromatography-mass spectrometry (GC/MS)-based metabolomic platform.We observed an elevation of sorbitol and fructose,and a decrease of myo-inositol in the renal cortex of db/db mice. Epalrestat reversed the renal accumulation of the polyol pathway metabolites of sorbitol and fructose,and increased myo-inositol level.Moreover,the upregulation of aldose reductase,fibronectin,collagen Ⅲ,and TGF-β1 in renal cortex of db/db mice was downregulated by epalrestat.The data suggested that epalrestat has protective effects on DN,and the inhibition ofaldose reductas and the modulation of polyol pathway in nephritic cells be a potentially therapeutic strategy for DN. | Jun He Hao-xue Gao Na Yang Xiao-dong Zhu Run-bin Sun Yuan Xie Cai-hong Zeng Jing-wei Zhang Jian-kun Wang Fei Ding Ji-ye Aa Guang-ji Wang | 2019 | Acta Pharmacologica Sinica2019，40，1： | 13 |
| 14 | Immune response to an indigenously developed r-Hepatitis B vaccine in mixed population: Study of an accelerated vaccination schedule显示文摘AIM: To establish the safety and efficacy of an indigenously developed r-hepatitis B vaccine using an accelerated schedule and to highlight the social awareness and commitment in preventing the spreading of hepatitis B virus infection.METHODS: The study was a multicentric, double blind,randomized (3:1) study using three doses of vaccine immunization schedule (20 μg for those above 10 years old and 10 μg for those below 10 years old) on d 0, 30and 60. One hundred and sixty-six subjects were enrolled(87 males and 76 females aged 5-35 years). The main outcome measure was assessment of immunogenicity and safety.RESULTS: A 100% seroconversion response was observed on the 30th d after the 1st injection in both the experimental groups. The sero-protection data reported a 41.2-65.6% response on the 30th d after the 1st injection and reached 100% on the 60th d. Descriptive statical analysis showed a geometric mean titer value of 13.77 mIU/mL in the test (BEVAC) group and 10.95 mIU/mL in the commercial control (ENGERIX-B) group on the 30th d after the 1st injection. The response on the 60th d showed a geometric mean titre value (GMT) of 519.84 mIU/mL in the BEVAC group and 475.46 mIU/mL in the ENGERIX-B group. On the 90th d, the antibody titer response was observed to be 2627.58 mIU/mL in the BEVAC group and 2272.72 mIU/mL in the ENGERIX-B group. Two subjects in each group experienced pains at injection site after the first vaccination. A total of six subjects in both groups experienced a solicited adverse reaction, which included pains, swelling and redness at the injection site, three subjects in the group-B had a pain at the injection site after the third dose. No other serious adverse events occurred and no dose-related local or general symptoms were observed during the study.CONCLUSION: The vaccine is safe, efficacious and immunogenic in comparison with the well documented ENGERIX-B. | A Chowdhury A Santra CM Habibullah AA Khan J Karunakaramaiah TSA Kishore AVR Raju S Lahiri | 2005 | World Journal of Gastroenterology2005，11，7： | 12 |
| 15 | Pharmacokinetic and metabolomic analyses of the neuroprotective effects of salvianolic acid A in a rat ischemic stroke model显示文摘 | Si-qi FENG Nan AA Jian-liang GENG Jing-qiu HUANG Run-bin SUN Chun GE Zhi-jian YANG Lian-sheng WANG Ji-ye AA Guang-ji WANG | 2017 | Acta Pharmacologica Sinica2017，38，11： | 12 |
| 16 | 国际胃袖状切除专家共识:基于>12000手术病例的最佳操作指南显示文摘腹腔镜胃袖状切除术(1aparoscopic sleeve gastrectomy,LSG)系相对较新的减重手术方式。因其操作相对简单、治疗肥胖合并疾病及减重效果明显,逐步得以广泛接受。目前美国代谢与减重手术协会将其推荐为肥胖症治疗的单独标准术式。2011年3月25~26日, | 苏远涛 徐安安 朱江帆 Diaz AA Arvidsson D Baker RS Basso N Bellanger D Boza C El Mourad H France M Gagner M Galvao-Neto M Higa KD Himpens J Hutchinson CM Jacobs M Jorgensen JO Jossart G Lakdawala M Nguyen NT Nocca D Prager G Pomp A Ramos AC Rosenthal RJ Shah S Vix M Wittgrove A Zundel N | 2013 | 中国微创外科杂志2013，13，9： | 12 |
| 17 | Combined treatment with apatinib and docetaxel in A549 xenograft mice and its cellular pharmacokinetic basis显示文摘 | Si-qi FENG Guang-ji WANG Jing-wei ZHANG Yuan XIE Run-bin SUN Fei FEI Jing-qiu HUANG Ying WANG Ji-ye AA Fang ZHOU | 2018 | Acta Pharmacologica Sinica2018，39，10： | 11 |
| 18 | 脊髓型颈椎病后路手术术后椎间盘骨赘复合物的大小变化:椎板成形术和椎板切除融合术的比较研究显示文摘椎板切除融合术(laminectomy with fusion,LF)和椎板成形术是治疗脊髓型颈椎病(cervical spondylotic myelopathy,CSM)的两种后路术式。业界认为其术中减压效果主要与脊髓从腹侧致压结构(如椎间盘骨赘复合物)向背侧漂移的程度有关,但事实上LF术后脊髓减压的另一机制是腹侧椎间盘骨赘复合物自发性吸收、减小,融合节段运动范围发生改变。本研究的目的是为了明确腹侧椎间盘骨赘复合物在椎板成形术后是否缩小,同时比较其与LF的差异。 | Aliboye RM Zoller SD Ashana AA 白朝晖 王建华 | 2017 | 中国骨科临床与基础研究杂志2017，9，4： | 10 |
| 19 | Isoflavones and phytosterols contained in Xuezhikang capsules modulate cholesterol homeostasis in high-fat diet mice显示文摘目的: Xuezhikang (XZK ) ,红酵母米饭的一篇摘录,广泛地在繁体中文药被使用了到对待心血管的疾病。三部分 F1, F2 和 F3 (首先包含 isoflavones, monacolins 或 phytosterols,分别地) 从 Xuezhikang 囊被提取。在这研究,我们评估了这些部分的类脂化合物阴沉的效果并且探索了 actions.Methods 的潜在的机制:与一本高脂肪的食谱( HFD )对待的老鼠是口头上地 adminis¬ ; tered lovastatin ( 10 mg· ; kg −1·d−1), XZK ( 1200 mg· ; kg −1·d−1), F1 ( 27.5 mg· ; kg −1·d−1), F2 ( 11.3 mg· ; kg −1·d−1 类脂化合物用商业酶的工具包被测量,并且基因的 mRNA 和蛋白质层次在胆固醇包含了,胆汁酸动态平衡用 qRT-PCR 和西方的污点分析被评估, respectively.Results : XZK 增加了类脂化合物和胆汁的烘便的排泄酸,减少的浆液 TC , TG 和 LDL-C 在40%的层次,55%和46%,分别地并且在31%的增加的浆液高级数据链路控制。F1 的管理镇压了在 24% 和 52% 的浆液 TC 和 TG,分别地并且 CYP7A1 的提高的肝的合成。它也通过 upregulating BSEP 和 downregulating NTCP 在烘便的排泄增加了胆汁酸的肝的消除 79% 。 F3 的管理减少了分别地,浆液 TC , TG 和 LDL-C 在33%,29%和39%铺平并且在28%的增加的浆液高级数据链路控制, sig¬ ;由禁止 NPC1L1 的抄写的胆固醇的 nificantly 减少的肠的吸收,和在96%的 TC , FC 和 CE 的提高的排泄,72%和101%分别地。F2 的管理显示出 lovastatin.Conclusion 的类似于那些的药理学效果: 在 XZK 的 Isoflavones 和 phytosterols 通过 lovastatin 不同于那些的机制在 HFD 老鼠施加胆固醇阴沉的效果。Isoflavones 和 phytosterols 以一种赞美方式行动:通过提高胆汁酸的消除并且分别地减少肠的胆固醇吸收。 | Dong FENG Jian-guo SUN Run-bin SUN Bing-chen OU-YANG Lan YAO Ji-ye AA Fang ZHOU Jing-wei ZHANG Jian ZHANG Guang-ji WANG | 2015 | Acta Pharmacologica Sinica2015，36，12： | 9 |
| 20 | In vitro assessment of the glucose-lowering effects of berberrubine-9-O-β-D-glucuronide, an active metabolite of berberrubine显示文摘Berberrubine (BRB ) 是在 vivo 比 BBR 显示出更强壮的葡萄糖阴沉的效果的 berberine (BBR ) 的主要代谢物。在另一方面, BRB 快速并且广泛地被使产生代射变化进 berberrubine-9-O -- 在在口头的管理以后的老鼠的 D-glucuronide (BRBG ) 。在这研究,我们在老鼠比较了 BRB 和 BRBG 的 pharmacokinetic 性质,并且探索了位于他们的葡萄糖阴沉的活动下面的机制。有导致 HFD 的多糖症的 C57BL/6 老鼠被管理 BRB (50 mg 吗?? | Na YANG Run-bin SUN Xing-long CHEN Le ZHEN Chun GE Yu-qing ZHAO Jun HE Jian-liang GENG Jia-hua GUO Xiao-yi YU Fei FEI Si-qi FENG Xuan-xuan ZHU Hong-bo WANG Feng-hua FU Ji-ye AA Guang-ji WANG | 2017 | Acta Pharmacologica Sinica2017，38，3： | 9 |
您所在的机构暂未开通此部分的功能，请联系管理员